# SymBio Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symbio-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.symbiopharma.com
- Total disclosed funding: $80M
- Latest round: Series E (Feb 25, 2011)
- Investors on record: 15

## About

Based in Japan, SymBio Pharmaceuticals Limited focuses on the development and commercialization of innovative biopharmaceuticals, primarily targeting unmet medical needs in oncology and other serious diseases.SymBio Pharmaceuticals Limited was founded in 2005 and is headquartered in Tokyo, Japan. The company specializes in biopharmaceutical development and has engaged in 10 notable deals, with its most recent deal occurring on May 16, 2022. Heights Capital Management invested JPY 662 million in a PIPE funding round, marking the total amount raised by the company at JPY 662 million. No significant changes in business strategy have been noted since its inception.SymBio Pharmaceuticals Limited specializes in the development and commercialization of biopharmaceutical products aimed at addressing unmet medical needs, particularly in oncology. Their flagship product, TREAKISYM (bendamustine hydrochloride), is used for treating relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. This product disrupts cancer cell DNA, leading to cell death. SymBio also offers additional products to enhance patient care in various therapeutic areas, distributing them primarily within Japan and other Asian regions to healthcare providers, hospitals, and clinics.In 2023, SymBio Pharmaceuticals Limited reported a revenue of JPY 39,871,065.6, with an EBITDA of JPY -5,087,799.5. The company generates revenue through direct sales to healthcare institutions and pharmaceutical distributors, utilizing a B2B transaction model where TREAKISYM is supplied under contractual agreements. Revenue is driven by ongoing treatment protocols and market-driven pricing strategies, ensuring a stable demand for its products.SymBio Pharmaceuticals Limited plans to leverage the recent investment of JPY 662 million from Heights Capital Management, expected to enhance growth opportunities. The company is focused on developing and launching new products, although specific details and timelines have not been disclosed. Additionally, there are intentions to expand into new geographic markets, aiming to reach broader patient demographics. The investment will play a crucial role in supporting these initiatives.

## Funding rounds

- Series E, Feb 25, 2011, $24M — Nippon Venture Capital, JAFCO Group, Life Science Venture Capital, Cephalon, SMBC Venture Capital
- Series D, Aug 21, 2009, $16M — Cephalon, WERU INVESTMENT
- Series C, Apr 15, 2009, $14M — Mitsubishi UFJ Capital, Cephalon
- Series B, Aug 31, 2006, $17M — JAFCO Group
- Series A, Oct 18, 2005, $8.8M — Zeron Capital Management, SBI Holdings, Japan Asia Investment Company, Sumitomo Corporation, Life Science Venture Capital, Tokyo Small and Medium Business Investment & Consultation, Daiichi Sankyo, EPS Corporation, Waseda University, WERU INVESTMENT

## Investors

- Zeron Capital Management (https://capitalatlas.ai/funds/zeron-capital-management) — Series A
- SBI Holdings — Series A
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series A
- Sumitomo Corporation — Series A
- Life Science Venture Capital (https://capitalatlas.ai/funds/life-science-venture-capital) — Series A, Series E
- Tokyo Small and Medium Business Investment & Consultation (https://capitalatlas.ai/funds/tokyo-small-and-medium-business-investment-consultation) — Series A
- Daiichi Sankyo — Series A
- EPS Corporation — Series A
- Waseda University — Series A
- WERU INVESTMENT (https://capitalatlas.ai/funds/weru-investment) — Series A, Series D
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series B, Series E
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Cephalon — Series C, Series D, Series E
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series E
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series E